Immunome, Inc. (IMNM)

Immunome, Inc. is trading at $18.21, down 0.44% on the session. The 50 day average sits at $23.40 and the 200 day at $22.55, which puts the stock in a uptrend. RSI is at 35.9, which reads as weak, and MACD is bullish crossover. Volume is average.

The nearest support is around $16.41 with resistance near $19.73, so that band frames the current range. Average daily movement is roughly $0.99, or about 5.5% of the share price, which is what any stop placement has to allow for. The overall health score of 36 out of 100 combines a trend score of 30, momentum of 44 and a risk score of 36.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.